Amphetamine Stimulant Prodrug denied as experimental or investigational by Humana?

Humana's specific coverage criteria for amphetamine stimulant prodrug are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied This as Experimental or Investigational

Humana may classify an amphetamine-class stimulant prodrug as "experimental or investigational" when the specific formulation, indication, or patient population falls outside what Humana's medical policy recognizes as established clinical practice. This can occur even when the drug holds FDA approval — for example, when the prescribed indication differs from the labeled use, when a formulation is newer and Humana's policy has not yet incorporated it, or when the claim was coded in a way that maps to an off-label use.

## Why Experimental Denials Are Frequently Overturned

If the drug is FDA-approved for the stated indication, the "experimental" label is factually incorrect and that error is the foundation of a strong appeal. Even for off-label uses, many state and federal protections require coverage when the use is supported by recognized compendia or major clinical-practice guidelines from organizations such as the applicable specialty society. ACA §2719 and ERISA §503 guarantee your right to a full internal appeal and independent external review. The external-review window is generally available for approximately four months after a final internal denial. An expedited 72-hour review is available when delay poses urgent risk.

## Appeal Process and Timeline

1. Obtain the denial letter identifying the specific policy language used to classify the drug as experimental. 2. Confirm the FDA approval status on DailyMed (dailymed.nlm.nih.gov) for the exact indication on the prescription. 3. File the internal appeal within Humana's deadline (typically 60 days from denial). Humana must respond within 30 days (pre-service) or 60 days (post-service). 4. If denied, request independent external review. External reviewers are not bound by Humana's internal policy definitions — they apply objective clinical standards.

## Documentation to Gather

• FDA label from DailyMed: Shows the approved indications. If the indication matches, attach this as Exhibit A.
• Applicable clinical-practice guideline: A reference to the relevant specialty society guideline (without quoting specific statistics) supporting use for this indication.
• Prescriber medical-necessity letter: States the diagnosis, explains why this drug is the appropriate evidence-based choice, and addresses why the use is not experimental.
• Diagnosis documentation: Office notes confirming the diagnosis that corresponds to the labeled or guideline-supported indication.
• Humana's experimental/investigational policy: Download it and identify the exact criteria used, so the appeal can address each one directly.

## Criteria-Mapping Structure

List each element of Humana's experimental/investigational definition in the left column. In the right column, cite the specific source — FDA label page, guideline organization name, prescriber statement, or chart note — that demonstrates the use is established rather than experimental. When the appeal shows that every criterion for the "experimental" label fails to apply, the denial has no remaining basis.